Margreet Geertruda Elia Maria Ausems
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margreet Geertruda Elia Maria Ausems has a total of 503 co-authors. Here are the top co-authors by number of shared publications:
- Eveline M. A. Bleiker
Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek , Amsterdam
7 shared publications - Maartje J. Hooning
Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
7 shared publications - Sandra van Dulmen
Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands; Department of Primary and Community Care, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands
7 shared publications - Frans Bl Hogervorst
Netherlands Cancer Institute, Amsterdam, The Netherlands
6 shared publications - Christie J Van Asperen
Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
5 shared publications - Encarna Gomez Garcia
Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
5 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Human Genetics
- Vol. 145 (1) , 73
Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer
Identifying pathogenic germline variants in men with metastatic prostate cancer is important for therapeutic options and for identifying relatives who may have a high cancer risk. To keep genetic testing costs manageable, it is important to identify which patients should be selected for testing. In this study, we compared expected costs and number of identified pathogenic variants in two scenarios: offering genetic testing to all men with metastatic prostate cancer versus testing only those with additional risk factors linked to a higher likelihood of carrying a pathogenic variant. Costs were evaluated with a mainstream genetic testing pathway, where testing is discussed by a non-genetic healthcare professional. Using Dutch national incidence data, predefined healthcare cost frameworks, and a hypothetical assumption for the acceptance rate of patients, we modelled total costs for the Netherlands and number of identified pathogenic variants for each approach. The costs of genetic testing and post-test counselling decreased threefold when applying selection criteria, compared to the scenario where all metastatic prostate cancer patients are eligible. However, applying selection criteria would result in missing 41% clinically relevant pathogenic germline variants that would otherwise be identified. This implies that, at national level, a discussion should be started regarding willingness to pay for identifying pathogenic germline variants.
- 29 August 2026
- Published by Springer Nature in Human Genetics
- Vol. 145 (1) , 73
Open AccessExpected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer
Identifying pathogenic germline variants in men with metastatic prostate cancer is important for therapeutic options and for identifying relatives who may have a high cancer risk. To keep genetic testing costs manageable, it is important to identify which patients should be selected for testing. In this study, we compared expected costs and number of identified pathogenic variants in two scenarios: offering genetic testing to all men with metastatic prostate cancer versus testing only those with additional risk factors linked to a higher likelihood of carrying a pathogenic variant. Costs were evaluated with a mainstream genetic testing pathway, where testing is discussed by a non-genetic healthcare professional. Using Dutch national incidence data, predefined healthcare cost frameworks, and a hypothetical assumption for the acceptance rate of patients, we modelled total costs for the Netherlands and number of identified pathogenic variants for each approach. The costs of genetic testing and post-test counselling decreased threefold when applying selection criteria, compared to the scenario where all metastatic prostate cancer patients are eligible. However, applying selection criteria would result in missing 41% clinically relevant pathogenic germline variants that would otherwise be identified. This implies that, at national level, a discussion should be started regarding willingness to pay for identifying pathogenic germline variants.
- Open Access
- 29 April 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70208
Digital genetic counseling services for cascade cardiogenetic testing
Digital interventions are potentially promising to improve accessibility and efficiency of genetic counseling services. However, current literature on user perspectives toward digital tools for cascade testing is limited. Therefore, this focus‐group study aimed to gain insights into the attitude and perspectives of probands, at‐risk relatives (ARR), and genetic healthcare professionals (HCP) toward digital innovations for assistance with both pretest and posttest counseling and cascade genetic testing in cardiogenetics. We conducted seven online focus groups, which were transcribed and thematically analyzed. In total, 37 individuals participated (10 probands, 11 ARR and 16 HCP). Thematic analysis of focus group transcripts showed a first theme of (1) acceptability of digital tools. Other identified themes were defined as “domains,” where digital tools impact traditional, in‐person clinical genetic care, being (2) family communication, (3) decision‐making, (4) care relations, and (5) the genetic care system. Participants expressed a predominantly positive attitude toward the digitization of (parts of) the predictive genetic counseling journey in cardiogenetics under the condition that access to human contact is preserved. In the clinical setting of predictive counseling, efforts should be made to ensure access to genetic services for all ARR and to protect in‐person involvement of HCP.
- 29 April 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70208
Open AccessDigital genetic counseling services for cascade cardiogenetic testing
Digital interventions are potentially promising to improve accessibility and efficiency of genetic counseling services. However, current literature on user perspectives toward digital tools for cascade testing is limited. Therefore, this focus‐group study aimed to gain insights into the attitude and perspectives of probands, at‐risk relatives (ARR), and genetic healthcare professionals (HCP) toward digital innovations for assistance with both pretest and posttest counseling and cascade genetic testing in cardiogenetics. We conducted seven online focus groups, which were transcribed and thematically analyzed. In total, 37 individuals participated (10 probands, 11 ARR and 16 HCP). Thematic analysis of focus group transcripts showed a first theme of (1) acceptability of digital tools. Other identified themes were defined as “domains,” where digital tools impact traditional, in‐person clinical genetic care, being (2) family communication, (3) decision‐making, (4) care relations, and (5) the genetic care system. Participants expressed a predominantly positive attitude toward the digitization of (parts of) the predictive genetic counseling journey in cardiogenetics under the condition that access to human contact is preserved. In the clinical setting of predictive counseling, efforts should be made to ensure access to genetic services for all ARR and to protect in‐person involvement of HCP.
- Open Access
- 18 November 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (4) , 85
Correction: Barriers and facilitators for medical oncologists in the further implementation of mainstream genetic testing in breast cancer care in the Netherlands
- 18 November 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (4) , 85
Open AccessCorrection: Barriers and facilitators for medical oncologists in the further implementation of mainstream genetic testing in breast cancer care in the Netherlands
- Open Access
- 14 October 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (4) , 1-10
Barriers and facilitators for medical oncologists in the further implementation of mainstream genetic testing in breast cancer care in the Netherlands
Only 67% of eligible patients with breast cancer currently undergo genetic testing. Mainstream genetic testing (i.e. healthcare professionals (HCPs) from outside the genetics field providing genetic counselling), also referred to asmainstreaming, leads to increased uptake of genetic testing. Unlike surgical oncologists, medical oncologists have not yet widely adopted mainstreaming. This study aims to identify barriers and facilitators for HCPs, in particular medical oncologists, in advancing the implementation of mainstreaming. Structured interviews were conducted with HCPs (predominantly medical oncologists) using the Constructive Technology Assessment (CTA) framework. Participants were recruited from all regions of the Netherlands, ensuring representation from academic medical centres, teaching hospitals and general hospitals. The interview data was analysed using thematic analysis. In this qualitative study, 12 medical oncologists, three nurse practitioners, three clinical geneticists, two clinical laboratory geneticists and one representative of a health insurer were interviewed. Lack of time and limited knowledge were the most commonly mentioned barriers, whilst effective cross-departmental collaboration and education were the most important facilitators. For medical oncologists specifically, financial compensation for the increased workload and the increasing importance of genetic testing for guiding therapy choices were found to be encouraging factors. This study identified several barriers and facilitators to mainstreaming being implemented by medical oncologists. Education to strengthen oncologists’ skills in discussing germline genetic testing may address knowledge gaps and time barriers. Alongside cross-departmental collaboration, these strategies could streamline genetic testing pathways. Further research should evaluate their implementation and effects on patient experience and equitable access.
- 14 October 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (4) , 1-10
Open AccessBarriers and facilitators for medical oncologists in the further implementation of mainstream genetic testing in breast cancer care in the Netherlands
Only 67% of eligible patients with breast cancer currently undergo genetic testing. Mainstream genetic testing (i.e. healthcare professionals (HCPs) from outside the genetics field providing genetic counselling), also referred to asmainstreaming, leads to increased uptake of genetic testing. Unlike surgical oncologists, medical oncologists have not yet widely adopted mainstreaming. This study aims to identify barriers and facilitators for HCPs, in particular medical oncologists, in advancing the implementation of mainstreaming. Structured interviews were conducted with HCPs (predominantly medical oncologists) using the Constructive Technology Assessment (CTA) framework. Participants were recruited from all regions of the Netherlands, ensuring representation from academic medical centres, teaching hospitals and general hospitals. The interview data was analysed using thematic analysis. In this qualitative study, 12 medical oncologists, three nurse practitioners, three clinical geneticists, two clinical laboratory geneticists and one representative of a health insurer were interviewed. Lack of time and limited knowledge were the most commonly mentioned barriers, whilst effective cross-departmental collaboration and education were the most important facilitators. For medical oncologists specifically, financial compensation for the increased workload and the increasing importance of genetic testing for guiding therapy choices were found to be encouraging factors. This study identified several barriers and facilitators to mainstreaming being implemented by medical oncologists. Education to strengthen oncologists’ skills in discussing germline genetic testing may address knowledge gaps and time barriers. Alongside cross-departmental collaboration, these strategies could streamline genetic testing pathways. Further research should evaluate their implementation and effects on patient experience and equitable access.
- Open Access
- 13 October 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (4) , 984-993
Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway
Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non‐genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision‐making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre‐test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23–0.57] and 0.44 [0.21–0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.
- 13 October 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (4) , 984-993
Open AccessExperiences of metastatic prostate cancer patients with a mainstream genetic testing pathway
Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non‐genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision‐making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre‐test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23–0.57] and 0.44 [0.21–0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.
- Open Access
- 2 September 2025
- Published by Wiley in BJU International
- Vol. 136 (6) , 1137-1144
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
Objective: To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa). Patients and methods: In this prospective multicentre cohort study ( n = 15 centres), germline genetic testing of the genes BRCA1 , BRCA2 , ATM , CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non‐oncological conditions. Additionally, we identified factors that increased the likelihood of carrying a gPV. Results: A total of 779 patients with mPCa underwent germline genetic testing, of whom 46 (5.9%) had a gPV in a DNA damage repair gene. Most gPVs were found in CHEK2 (1100delC variant), ATM and BRCA2 , all significantly more prevalent than in the reference population (odds ratios 2.4, 2.8 and 3.1, respectively). The prevalence of gPVs in BRCA1 and PALB2 was not significantly increased. Patients with a second primary cancer, a first‐ or second‐degree relative with breast cancer at age < 50 years, or pancreatic cancer, or Jewish ancestry had the highest likelihood of carrying a gPV. Conclusion: We found that gPVs in CHEK2 , ATM and BRCA2 were associated with men presenting with mPCa. Several factors increased the likelihood of carrying such a variant and, in these cases, healthcare professionals should be aware of the need to offer germline genetic testing.
- 2 September 2025
- Published by Wiley in BJU International
- Vol. 136 (6) , 1137-1144
Open AccessPrevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
Objective: To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa). Patients and methods: In this prospective multicentre cohort study ( n = 15 centres), germline genetic testing of the genes BRCA1 , BRCA2 , ATM , CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non‐oncological conditions. Additionally, we identified factors that increased the likelihood of carrying a gPV. Results: A total of 779 patients with mPCa underwent germline genetic testing, of whom 46 (5.9%) had a gPV in a DNA damage repair gene. Most gPVs were found in CHEK2 (1100delC variant), ATM and BRCA2 , all significantly more prevalent than in the reference population (odds ratios 2.4, 2.8 and 3.1, respectively). The prevalence of gPVs in BRCA1 and PALB2 was not significantly increased. Patients with a second primary cancer, a first‐ or second‐degree relative with breast cancer at age < 50 years, or pancreatic cancer, or Jewish ancestry had the highest likelihood of carrying a gPV. Conclusion: We found that gPVs in CHEK2 , ATM and BRCA2 were associated with men presenting with mPCa. Several factors increased the likelihood of carrying such a variant and, in these cases, healthcare professionals should be aware of the need to offer germline genetic testing.
- Open Access
- 14 July 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 1-10
The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study
Genetic testing in breast cancer patients is important for the patient’s local and systemic treatment choices and follow-up, as well as for their family members. Not all eligible patients currently undergo genetic testing and disparities persist in genetic testing uptake. It is unknown on the large scale whether pre-test counselling by non-genetic healthcare professionals (HCPs)–mainstream genetic testing (MGT) – improves overall genetic testing uptake and reduces disparities. We examined the impact of MGT on germline genetic testing uptake in general and in subgroups of socioeconomic status (SES) in particular. In this retrospective nationwide cohort study, we selected all breast cancer patients from the Netherlands Cancer Registry who were eligible for genetic testing according to patient and tumour characteristics under the Dutch guidelines and who were diagnosed between 1-Jan-2017 and 31-Dec-2022. The primary outcome was genetic testing uptake. The influence of MGT and SES on overall uptake and uptake across different SES levels was evaluated using chi-squared tests and multivariable logistic regression analyses. A total of 12,071 breast cancer patients were included. Overall genetic testing uptake was 67%: 78% for MGT versus 63% in referral to a genetics department (RGD) (p < 0.001) with significantly higher odds of receiving genetic testing for MGT versus RGD (OR 2.48, 95% CI 2.14–2.87). Patients with low SES showed significantly lower odds of receiving genetic testing compared to those with a high SES (OR 0.71, 95% CI 0.61–0.83). In MGT, no significant difference was found between low and high SES in the likelihood of receiving genetic testing (OR 0.75, 95% CI 0.50–1.13). MGT significantly increases genetic testing uptake among all eligible patients and across all SES subgroups, strongly encouraging further implementation of MGT. Educating HCPs about current disparities in genetic testing is essential to improve health equity in breast cancer care.
- 14 July 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 1-10
Open AccessThe impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study
Genetic testing in breast cancer patients is important for the patient’s local and systemic treatment choices and follow-up, as well as for their family members. Not all eligible patients currently undergo genetic testing and disparities persist in genetic testing uptake. It is unknown on the large scale whether pre-test counselling by non-genetic healthcare professionals (HCPs)–mainstream genetic testing (MGT) – improves overall genetic testing uptake and reduces disparities. We examined the impact of MGT on germline genetic testing uptake in general and in subgroups of socioeconomic status (SES) in particular. In this retrospective nationwide cohort study, we selected all breast cancer patients from the Netherlands Cancer Registry who were eligible for genetic testing according to patient and tumour characteristics under the Dutch guidelines and who were diagnosed between 1-Jan-2017 and 31-Dec-2022. The primary outcome was genetic testing uptake. The influence of MGT and SES on overall uptake and uptake across different SES levels was evaluated using chi-squared tests and multivariable logistic regression analyses. A total of 12,071 breast cancer patients were included. Overall genetic testing uptake was 67%: 78% for MGT versus 63% in referral to a genetics department (RGD) (p < 0.001) with significantly higher odds of receiving genetic testing for MGT versus RGD (OR 2.48, 95% CI 2.14–2.87). Patients with low SES showed significantly lower odds of receiving genetic testing compared to those with a high SES (OR 0.71, 95% CI 0.61–0.83). In MGT, no significant difference was found between low and high SES in the likelihood of receiving genetic testing (OR 0.75, 95% CI 0.50–1.13). MGT significantly increases genetic testing uptake among all eligible patients and across all SES subgroups, strongly encouraging further implementation of MGT. Educating HCPs about current disparities in genetic testing is essential to improve health equity in breast cancer care.
- Open Access
Digital genetic counselling services for cascade cardiogenetic testing: a focus group study on proband, relative, and provider perspectives
Digital interventions are potentially promising to improve accessibility and efficiency of genetic counselling services. However, current literature on stakeholder perspectives towards digital tools for cascade testing is limited. Therefore, this focus group study aimed to gain insights into the attitude and perspectives of probands, at-risk relatives (ARR), and genetic healthcare professionals (HCP) towards digital innovations for assistance with both pre-test and post-test counselling and cascade genetic testing in cardiogenetics. We conducted seven online focus groups, which where transcribed and thematically analysed. In total, 37 individuals participated (10 probands, 11 ARR and 16 HCP). Thematic analysis of focus group transcripts showed a first theme of (1) acceptability of digital tools. Other identified themes were defined as ‘domains’ where digital tools impact traditional, in-person clinical genetic care, being: (2) family communication, (3) decision-making, (4) care relations, and (5) the genetic care system. Stakeholders expressed a predominantly positive attitude towards digitisation of (parts of) the predictive genetic counselling in cardiogenetics, under the condition that access to human contact is preserved. In the clinical setting of predictive counselling, efforts should be made to ensure access to genetic services for all ARR and to protect in-person involvement of HCP.
Open AccessDigital genetic counselling services for cascade cardiogenetic testing: a focus group study on proband, relative, and provider perspectives
Digital interventions are potentially promising to improve accessibility and efficiency of genetic counselling services. However, current literature on stakeholder perspectives towards digital tools for cascade testing is limited. Therefore, this focus group study aimed to gain insights into the attitude and perspectives of probands, at-risk relatives (ARR), and genetic healthcare professionals (HCP) towards digital innovations for assistance with both pre-test and post-test counselling and cascade genetic testing in cardiogenetics. We conducted seven online focus groups, which where transcribed and thematically analysed. In total, 37 individuals participated (10 probands, 11 ARR and 16 HCP). Thematic analysis of focus group transcripts showed a first theme of (1) acceptability of digital tools. Other identified themes were defined as ‘domains’ where digital tools impact traditional, in-person clinical genetic care, being: (2) family communication, (3) decision-making, (4) care relations, and (5) the genetic care system. Stakeholders expressed a predominantly positive attitude towards digitisation of (parts of) the predictive genetic counselling in cardiogenetics, under the condition that access to human contact is preserved. In the clinical setting of predictive counselling, efforts should be made to ensure access to genetic services for all ARR and to protect in-person involvement of HCP.
- 23 November 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (4) , 719-727
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers
Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents high-grade serous carcinoma (HGSC) in BRCA1/2 germline pathogenic variant (GPV) carriers. Still, some women develop HGSC after RRSO without pathologic findings. This study assessed long-term incidence and risk factors for developing HGSC after RRSO without pathologic findings. BRCA1/2 GPV carriers were selected from Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) cohort. Follow-up data for HGSC after RRSO were obtained from the Dutch Nationwide Pathology Databank (PALGA) and confirmed by histopathological review. Cumulative incidence rates of HGSC were calculated using Kaplan-Meier analyses. Cox proportional hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with an increased risk of HGSC following RRSO without pathologic findings. A total of 2519 women were included, with a median follow-up of 13.4 years (range: 0.0-27.6). The 20-years cumulative incidence rate of HGSC was 1.5% (95% CI: 0.0-2.1) for BRCA1 and 0.2% (95% CI: 0.0-1.4) for BRCA2 GPV carriers. All women who developed HGSC underwent RRSO after the recommended age. Incomplete embedding of the RRSO specimen (HR: 4.2, 95% CI: 1.4-12.6), higher age at RRSO (HR per year: 1.1, 95% CI: 1.0-1.1), and carrying a BRCA1 GPV (HR: 12.1, 95% CI: 1.6-91.2) were associated with increased risk of HGSC. In BRCA1/2 GPV carriers, long-term incidence of HGSC after RRSO without pathologic findings was low. Strict adherence to guidelines regarding timely RRSO followed by complete specimen embedding can further reduce the risk of HGSC in the years following RRSO.
- 23 November 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (4) , 719-727
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers
Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents high-grade serous carcinoma (HGSC) in BRCA1/2 germline pathogenic variant (GPV) carriers. Still, some women develop HGSC after RRSO without pathologic findings. This study assessed long-term incidence and risk factors for developing HGSC after RRSO without pathologic findings. BRCA1/2 GPV carriers were selected from Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) cohort. Follow-up data for HGSC after RRSO were obtained from the Dutch Nationwide Pathology Databank (PALGA) and confirmed by histopathological review. Cumulative incidence rates of HGSC were calculated using Kaplan-Meier analyses. Cox proportional hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with an increased risk of HGSC following RRSO without pathologic findings. A total of 2519 women were included, with a median follow-up of 13.4 years (range: 0.0-27.6). The 20-years cumulative incidence rate of HGSC was 1.5% (95% CI: 0.0-2.1) for BRCA1 and 0.2% (95% CI: 0.0-1.4) for BRCA2 GPV carriers. All women who developed HGSC underwent RRSO after the recommended age. Incomplete embedding of the RRSO specimen (HR: 4.2, 95% CI: 1.4-12.6), higher age at RRSO (HR per year: 1.1, 95% CI: 1.0-1.1), and carrying a BRCA1 GPV (HR: 12.1, 95% CI: 1.6-91.2) were associated with increased risk of HGSC. In BRCA1/2 GPV carriers, long-term incidence of HGSC after RRSO without pathologic findings was low. Strict adherence to guidelines regarding timely RRSO followed by complete specimen embedding can further reduce the risk of HGSC in the years following RRSO.
- Open Access
Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2
Purpose: CHEK2 c.1100delC is associated with an increased breast cancer risk in women. While this variant is prevalent in the Netherlands (1% in the general population), knowledge of aetiology and prognosis of breast cancer and other tumours in CHEK2 c.1100delC carriers is lacking. The nationwide HEreditary Breast and Ovarian cancer study the Netherlands (Hebon) cohort aims to answer study questions in families with an increased risk of breast cancer and ovarian cancer. While initially focusing on BRCA1/2 -variant families, Hebon gradually expanded to include pathogenic variants in other genes associated with breast and/or ovarian cancer over time. This provides an excellent setting to establish a cohort to ultimately study the impact of CHEK2 c.1100delC on cancer risk prediction and surveillance, breast cancer treatment and prognosis. Participants: We invited all heterozygous and homozygous CHEK2 c.1100delC indexes and tested female relatives. 1802 women were included, of whom 1374 were heterozygotes and 938 were breast cancer cases. Pedigrees were collected from all clinical genetic departments. Furthermore, participants completed a detailed questionnaire on hormonal and lifestyle factors, family history, cancer diagnosis and treatment. Findings to date: Mean age at study inclusion was 53 years. Linkage with the Netherlands Cancer Registry showed a younger age at diagnosis in homozygotes (mean age 41.7 years) and heterozygotes (47.9 years) than non-carriers (51.2 years). Furthermore, carriers were more often diagnosed with grade 2, oestrogen receptor-positive breast cancer and more often developed contralateral breast cancer than non-carriers. Most women consumed alcohol regularly and about half never smoked. Future plans: Further data linkages with the Netherlands Cancer Registry will allow prospective follow-up and breast cancer risk assessment in unaffected women at the time of genetic testing, risk of contralateral breast cancer and survival in patients with breast cancer. Also, linkage with the nationwide network and registry of histopathology and cytopathology in The Netherlands (PALGA) allows us to retrieve tumour samples to study tumourigenesis.
Open AccessCohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2
Purpose: CHEK2 c.1100delC is associated with an increased breast cancer risk in women. While this variant is prevalent in the Netherlands (1% in the general population), knowledge of aetiology and prognosis of breast cancer and other tumours in CHEK2 c.1100delC carriers is lacking. The nationwide HEreditary Breast and Ovarian cancer study the Netherlands (Hebon) cohort aims to answer study questions in families with an increased risk of breast cancer and ovarian cancer. While initially focusing on BRCA1/2 -variant families, Hebon gradually expanded to include pathogenic variants in other genes associated with breast and/or ovarian cancer over time. This provides an excellent setting to establish a cohort to ultimately study the impact of CHEK2 c.1100delC on cancer risk prediction and surveillance, breast cancer treatment and prognosis. Participants: We invited all heterozygous and homozygous CHEK2 c.1100delC indexes and tested female relatives. 1802 women were included, of whom 1374 were heterozygotes and 938 were breast cancer cases. Pedigrees were collected from all clinical genetic departments. Furthermore, participants completed a detailed questionnaire on hormonal and lifestyle factors, family history, cancer diagnosis and treatment. Findings to date: Mean age at study inclusion was 53 years. Linkage with the Netherlands Cancer Registry showed a younger age at diagnosis in homozygotes (mean age 41.7 years) and heterozygotes (47.9 years) than non-carriers (51.2 years). Furthermore, carriers were more often diagnosed with grade 2, oestrogen receptor-positive breast cancer and more often developed contralateral breast cancer than non-carriers. Most women consumed alcohol regularly and about half never smoked. Future plans: Further data linkages with the Netherlands Cancer Registry will allow prospective follow-up and breast cancer risk assessment in unaffected women at the time of genetic testing, risk of contralateral breast cancer and survival in patients with breast cancer. Also, linkage with the nationwide network and registry of histopathology and cytopathology in The Netherlands (PALGA) allows us to retrieve tumour samples to study tumourigenesis.